Chemistry:SB-699551

From HandWiki
Short description: Chemical compound
SB-699551
SB-699,551 structure.png
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC34H45N3O
Molar mass511.754 g·mol−1
3D model (JSmol)
  (verify)

SB-699551 is a drug which was the first compound developed to act as a selective antagonist for the serotonin receptor 5-HT5A, with selectivity of around 100x over other serotonin receptor subtypes.[1] Multiple therapeutic roles have been suggested for 5-HT5A ligands due to the presence of this receptor in several areas of the brain, but research is still at an early stage,[2] In animal studies, SB-699551 was found to block cue-mediated responding to LSD, again suggesting an antipsychotic type of activity.[3] It also reduces the viability of certain types of cancer cells in vitro, suggesting the 5-HT5A receptor as a possible target for novel chemotherapy drugs.[4][5]

References

  1. "SB-699551-A (3-cyclopentyl-N-[2-(dimethylamino)ethyl]-N-[(4'-{[(2-phenylethyl)amino]methyl}-4-biphenylyl)methyl]propanamide dihydrochloride), a novel 5-ht5A receptor-selective antagonist, enhances 5-HT neuronal function: Evidence for an autoreceptor role for the 5-ht5A receptor in guinea pig brain". Neuropharmacology 51 (3): 566–577. September 2006. doi:10.1016/j.neuropharm.2006.04.019. PMID 16846620. 
  2. "The effects of a 5-HT5A receptor antagonist in a ketamine-based rat model of cognitive dysfunction and the negative symptoms of schizophrenia". Neuropharmacology 105: 351–360. June 2016. doi:10.1016/j.neuropharm.2016.01.035. PMID 26826431. 
  3. "Serotonin type 5A receptor antagonists inhibit D-lysergic acid diethylamide discriminatory cue in rats". Journal of Psychopharmacology 33 (11): 1447–1455. November 2019. doi:10.1177/0269881119867603. PMID 31452444. 
  4. "High-throughput screen identifies 5-HT receptor as a modulator of AR and a therapeutic target for prostate cancer". The Prostate 80 (11): 885–894. August 2020. doi:10.1002/pros.24022. PMID 32483877. 
  5. "Antagonists of the serotonin receptor 5A target human breast tumor initiating cells". BMC Cancer 20 (1): 724. August 2020. doi:10.1186/s12885-020-07193-6. PMID 32758183.